Airfinity’s solution combines push and platform experience:
Airfinity was the first company to build a science intelligence tool dedicated to COVID-19, supported by a large expert team who have followed the pandemic from the beginning. We provide global coverage of four related areas:
Never miss out and allow your team to go deeper into the data to understand how tomorrow's science will impact your company and industry.
Our information is subjected to rigorous Q&A multiple times and verified by therapy area specialists prior to publication. Through partnerships, critical data points are also confirmed by third party sources. All information is linked to its underlying source and a clear methodology provided.
Our forecasts have been proven to be amongst the most accurate available and delivered significant edge to our clients. Airfinity enables your organisation to better predict science, and its related market and macro developments. Countries that have based their decisions on Airfinity's insights have generally fared better under COVID and many of the world's most successful hedgefunds and investors have outperformed their peers and the market with the help of Airfinity.
Our solution allows teams to save considerable time on their own data collection and analysis so that resources can be focused on making the right decisions, informed by a trusted partner.
Deep dives on vaccine and therapeutic candidates in pre-clinical and clinical trials with real time meta-reviews and competitor comparisons on efficacy, effectiveness, cost-benefit and safety incorporating KOL sentiment analysis scraped from conferences and social media.
We deliver critical data, information and insights to global decision makers across pharmaceuticals, med- and biotech companies, governments, corporates and investors.
Our experts will:
Complete the form to schedule your demo.